Clinical study shows AstaReal® astaxanthin effective in proactive beautyJul 20, 2017
TOKYO, JAPAN – 2017/ 07/ 20 – The AstaReal Group has once again proved to be the research leader in scientifically-backed, natural astaxanthin by further adding to their vast clinical database. The newest study, a combined in vitro and in vivo clinical study, shows AstaReal astaxanthin has proactive beauty benefits for the skin.
First, a cell assay was performed to analyse effects of astaxanthin on skin cells (epidermal keratinocytes) when exposed to UV-B irradiation. Following this, a clinical study measuring wrinkle depth and skin moisture was conducted on 65 healthy females of 35-60 years. Additional tests were conducted on the cells of the stratum corneum to investigate the level of inflammatory cytokines.
The findings of this study suggest that AstaReal® astaxanthin has the potential to inhibit inflammation-mediated skin deterioration, such as wrinkle formation and seasonal skin moisture decline, thereby retarding the progression of skin aging. This study was conducted during the period with the most adverse seasonal conditions for skin, which was evident as both skin moisture and deep wrinkles significantly worsened in the placebo group, however despite the conditions, the natural astaxanthin group maintained their skin condition and significant worsening was not observed.
The study proved that the long-term, anti-inflammatory effect of AstaReal® astaxanthin supplementation may fight skin deterioration caused by seasonal changes in humidity and sunlight, and consequently slow the skin aging process.
This study builds upon previous studies by AstaReal which have shown that natural astaxanthin can improve moisture content, texture, elasticity, fine lines & wrinkles, sebum production, trans-epidermal water loss, and reduce age spots in skin.
Tominaga, Kumi, et al. “Protective effects of astaxanthin on skin deterioration.” Journal of Clinical Biochemistry and Nutrition, vol. 61, no. 1, 2017, pp. 33–39., doi:10.3164/jcbn.17-35.
AstaReal is part of the AstaReal Group, which is fully owned by the Fuji Chemical Group of Japan. AstaReal produces natural astaxanthin from the freshwater Haematococcus pluvialis microalga cultivated at facilities in Sweden and the USA, with sales offices in Japan, Sweden, USA, Singapore, Australia and India. The AstaReal Group is the global pioneer and expert in natural astaxanthin cultivation, R&D and clinical science, producing the world’s first commercial astaxanthin in 1994.
For further information about astaxanthin and the AstaReal Group, please contact: